Neko Health Valuation, Funding & Investors

Ro is a New York City-based telehealth company that combines online physician consultations, its own pharmacy, laboratory testing and in-home care, with patients paying without insurance. Zachariah Reitano, Saman Rahmanian and Rob Schutz founded it in October 2017 as Roman, an erectile dysfunction service, and it has since added services for women's health, weight management and fertility. Its prescriptions include GLP-1 obesity medicines, and it works with Eli Lilly (Zepbound vials through LillyDirect, December 2024) and Novo Nordisk (the Wegovy pill, January 2026). Sacra estimates revenue of $360 million in 2023 and $598 million in 2024, up 66 percent. Ro earns revenue from telehealth visits and from prescriptions and products fulfilled through its pharmacy network. It has raised about $1 billion of primary capital, most recently $150 million in February 2022 at a $7 billion valuation led by ShawSpring Partners. Acquisitions include Workpath (December 2020), Modern Fertility (2021, more than $225 million) and Kit (2021).

Sonic Healthcare is an Australian medical diagnostics company that provides pathology and clinical laboratory services, diagnostic imaging and primary care medical services. It was listed on the Australian Securities Exchange in 1987 and has grown largely through acquisitions in Australia, New Zealand, the United Kingdom, the United States, Germany, Switzerland and Belgium. The group reported revenue of A$9.6 billion and a net profit of A$514 million for the year to June 2025 and employs more than 45,000 people. It describes itself as the third largest provider of pathology and clinical laboratory services in the world and the largest private laboratory operator in Australia, Germany, Switzerland and the United Kingdom. It is also the second largest participant in Australian diagnostic imaging, and its Sonic Clinical Services division runs medical centres, skin cancer clinics and occupational health services in Australia. Revenue comes from fees for tests and scans paid by patients, Medicare and other public and private payers, and from hospital and NHS laboratory outsourcing contracts. The company is headquartered in Sydney and operates through a decentralised structure built around what it calls Medical Leadership.

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Diasorin is an Italian in vitro diagnostics company headquartered in Saluggia that develops, makes and sells reagent kits for immunodiagnostics and molecular diagnostics. Since July 2021 it has also been active in life science through the Luminex business. Its production sites are in Italy, Germany, the United Kingdom and the United States, and after the Luminex deal it added plants in North America. Its shares are listed on Euronext Milan and it sells in five continents. It entered molecular diagnostics in 2016 by buying the Focus Diagnostics product business from Quest Diagnostics. It bought Luminex in 2021 for about USD 1.8 billion.

Seoul-based Olive Healthcare develops noninvasive near-infrared devices for abdominal fat measurement and breast cancer screening. Employing AI algorithms and big data, its portable scanners provide customized diagnostic reports without radiation.

Sword Health is a digital health company that delivers physical therapy and related care through an AI-guided platform combined with licensed clinicians. It was founded in Portugal in 2015 by Virgilio Bento and Marcio Colunas and operates in the United States, Ireland and Portugal. Its programs cover musculoskeletal pain, women's health, cardiometabolic risk and mental health, and are sold to employers and health plans, which pay for their members to use the service. The company said it works with more than 1,000 enterprise clients and has raised more than 300 million dollars from investors including Khosla Ventures, General Catalyst, Transformation Capital and Founders Fund. It raised 40 million dollars at a 4 billion dollar valuation in June 2025 and bought Surgery Hero in 2025 and Kaia Health in 2026. In August 2026 it announced an agreement to acquire Headspace.

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.

Noom is a digital health platform combining psychology, AI, and human coaching for wellness goals including weight management, diabetes prevention, and stress reduction. New York City-headquartered, it secured grants from the National Institutes of Health and became the first mobile app certified by the Centers for Disease Control for diabetes prevention. Noom serves millions via app-based programs with behavioral tracking and virtual coaching sessions. Recognized by Inc and Fortune for workplace culture, it operates globally with personalized nutrition and habit-building modules.

Hippocratic AI is a San Francisco-headquartered developer of large language models optimized for non-diagnostic healthcare interactions. Its platform deploys AI agents for tasks like preoperative education, discharge instructions, and chronic disease follow-ups via phone or text. Built on a multi-agent architecture with clinician oversight, the system includes an agent marketplace for specialties such as cardiology and oncology. Health systems integrate agents into workflows for patient outreach and triage support.

Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.

Shanghai United Imaging Healthcare Co Ltd provides customers with high-performance medical imaging equipment, radiotherapy products, life science instruments, and medical digitalization and intelligent solutions. The company’s products include MRI systems, CT scanners, X-ray imaging equipment, molecular imaging systems, radiotherapy linear accelerators, and life science instruments.

Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2026, Pro Medicus earned 90% of revenue in North America, 7% from Australia, and the remaining 3% in Europe.

Telix Pharmaceuticals is a biopharmaceutical company that develops and commercialises diagnostic and therapeutic radiopharmaceuticals for oncology and rare diseases. Its portfolio covers imaging agents and targeted radiation therapies used in prostate, kidney and brain cancers, built around a theranostic approach that pairs diagnosis with treatment. The company sells commercial imaging products to hospitals and nuclear medicine centres and runs a clinical pipeline of therapeutic candidates. It is headquartered in Melbourne, Australia, was founded in 2015, and is listed on the ASX and Nasdaq. Through its agreement to acquire ITM in 2026 it extends into radioisotope manufacturing and distribution.

NewLimit is a South San Francisco-headquartered biotechnology company advancing epigenetic reprogramming to extend human healthspan. The firm develops therapies restoring cellular function in aging tissues, targeting diseases like neurodegeneration and cardiovascular conditions. NewLimit's platform integrates machine learning with partial reprogramming techniques to identify optimal rejuvenation protocols.

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.